ABBV Earnings

ABBV reported its FY2025Q4 earnings on 2026-02-04, showcasing a revenue of 0.00 against an estimate of 16.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected 2.65 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ABBV's FY2025Q4 earnings announcement on 2026-02-04, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, ABBV's stock price tends to shift by an average of -1.30% in the 10 days leading up to earnings and +1.52% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ABBV’s annual revenue to reach 16.00B, while the EPS is projected at 3.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.39% and EPS estimates Revise Upward by 0.38% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ABBV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.39%, while EPS estimates moved Revise Upward by 0.38% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ABBV's stock price typically moves by -1.30% in the 10 days before its earnings and +1.52% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 3.00 and revenue of 16.00B.

AbbVie has raised its revenue and EPS guidance, indicating strong financial performance. Skyrizi and Rinvoq are expected to exceed guidance, and there is optimism in the neuroscience and immunology portfolios. Despite challenges in the aesthetics market and Humira erosion, the company anticipates growth driven by pipeline advancements and strategic acquisitions. The Q&A highlighted strong competitive positioning and market share gains. While some uncertainties remain, the overall sentiment is positive, suggesting a stock price increase in the short term.